PDUFA date set for February 7, 2025 If approved by the FDA, label would expand to include alternative injection sites in the thigh, buttock and back of the arm for induction and maintenance as well as ...
The trial also demonstrated that administering the second SUBLOCADE injection just one week after the first was well tolerated in both treatment arms as the safety profile up to injection two was ...
Patients not already receiving buprenorphine can receive the first injection of Sublocade following a single dose of transmucosal buprenorphine and a 1 hour observation period to confirm tolerability.
Data show rapid initiation with once-monthly SUBLOCADE significantly improves retention in opioid use disorder (OUD) patients, especially among fentanyl-positive participants. Study also administered ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Compared to patients adherent to monthly injectable buprenorphine, patients on other MOUD (adherent and non-adherent) were 3.5 to 8.1x more ...
RICHMOND, Va., Oct. 15, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) this week published compelling results from a multicenter, open-label clinical trial published in JAMA Network Open. Two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results